Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

Recently the Company announced that more than 133 patients have been enrolled in its MAESTRO-03 trial. An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Frederick, MD (PRWEB) November 21, 2014 ... sample management solutions provider, has released Limfinity® version ... more installation projects of Limfinity® than ever in ... majority configuration and minority framework enhancement. Limfinity® version ... goes far above and beyond bug fixes! , ...
(Date:11/22/2014)... LAVAL, Quebec , November 21, 2014 ... Martensen wechselt als Chief Commercial Officer zu KLOX ... zum SVP der Unternehmensentwicklung und Chief Financial Officer bestellt ... in Europa mit der Vermarktung seines jüngst zugelassenen Behandlungssystems ... Technologies Inc. ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, ...
(Date:11/21/2014)... 20, 2014 Author Matthew J. Pallamary’s ... the Other Side” published as a tribute to ... the “Fiction: Short Story” category of the 2014 ... and CEO of USA Book News, said this year’s ... publishers, including Simon & Schuster, Penguin, John Wiley & ...
(Date:11/21/2014)... 21, 2014 Why did Stephen Hawking ... Einstein so instantly recognizable? Why have they become icons ... and author Hilton Ratcliffe seeks out the answers to ... all to do with science. In " Stephen Hawking ... November 21, 2014), Ratcliffe puts it plainly: , ...
Breaking Biology Technology:RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4
... DIEGO, Feb. 10 ADVENTRX Pharmaceuticals, Inc.,(NYSE Alternext ... written,indications of interest from numerous companies representing a ... evaluating all proposals and,options. In December 2008, ... range,of strategic options, including the sale or disposition ...
... OrthoCare Innovations, LLC is pleased,to announce that former ... Nelson, MD have joined its board of medical ... former Medicare directors to the,Centers for Medicare and ... Carrier), will also consult with the,Company on issues ...
... Feb. 10 /PRNewswire-Asia/ -- Sundia MediTech, a CRO,company ... based in Florida,U.S.A. jointly announced their 2 year ... International Conference yesterday in San Diego,USA. So far ... 2,more candidates to be identified within the next ...
Cached Biology Technology:ADVENTRX Provides Update on Strategic Transaction Process 2ADVENTRX Provides Update on Strategic Transaction Process 3ADVENTRX Provides Update on Strategic Transaction Process 4Former SADMERC Medical Directors Join OrthoCare Innovations as Medical and Scientific Advisory Board Members and Strategic Advisors 2Sundia MediTech and Xcovery Announce Big Success in Drug Discovery 2
(Date:11/7/2014)...  In conjunction with the Glendale ... Foundation of the Verdugos has announced the " GLENDALE ... $250,000 initiative to keep the Verdugo Regional Crime Lab operational ... months of existence, the Lab has processed more than 400 ... enforcement. "Because our number one priority is the ...
(Date:11/6/2014)... occur because of metastasis, yet progress in preventing ... , "It,s been particularly challenging to design drugs ... fellow in systems biology at Harvard Medical School. ... after they,ve already metastasized." , Gujral and colleagues ... help researchers better understand how metastasis begins. Their ...
(Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... has placed increasing demands on available water resources. In ... Nevada, where the population approached two million people. The ... that features frequent severe drought conditions has created an ... to meet resident and visitor demand., Las Vegas operates ...
... The National Institute of Child Health and Development (NICHD) of ... of Medicine of Yeshiva University a $7.5 million grant to ... Research (SCCPIR).One of only 13 such centers in the country ... center will focus on a wide range of diseases of ...
... World Water Day on Sunday, 22 March aims ... clean drinking water on our planet. In a densely ... than ever before. Helmholtz scientists in the research ... precisely these problems. In cooperation with partners from other ...
Cached Biology News:Keeping golf courses green when fresh water is limited 2Keeping golf courses green when fresh water is limited 3NIH funds research center for women's reproductive health at Einstein 2NIH funds research center for women's reproductive health at Einstein 3Research to secure a safe water supply 2Research to secure a safe water supply 3Research to secure a safe water supply 4
... Polystyrene covers can be used ... Ridged covers for stacking of ... covers for use with automated ... ridged and non-ridged, are available ...
Designed for use with all 96-well SPRI reagent kits. Used with round bottom 96-well microplates, and 96-well thermal cycling plates....
... HistoMark Biotin Streptavidin-HRP Systems provide rapid, ... intracellular antigens in frozen or paraffin-embedded ... These systems also facilitate double or ... be performed simultaneously with primary antibodies ...
... 96- or 384-well PCR plates Dimples on both ... 96-tube plates End tabs on Thermo-Mat™ 384 fit ... Efficient sealing is achieved with either Thermo-Mat™ 96 or ... hot lid thermal cyclers Fully autoclavable ...
Biology Products: